'GPC Biotech' (also referred to as ''GPCbiotech'' and ''GPC-Biotech'') is a German
biopharmaceutical company. The company's mission statement reads "... to discover, develop and commercialize new anticancer drugs."
Founded in 1997, the company was held privately until
May 2000 when an
initial public offering was made on the now defunct German
Neuer Markt. Subsequent to the closing of the Neuer, GPC refinanced in
June 2004 through a public stock offering and listed
ADRs on
NASDAQ.
In
March 2000, the company acquired
Mitotix, a United States biotechnology firm located in
Cambridge, Massachusetts. This acquisition has led to the company having ~50% of its employees based in the United States and the remaining 50% in Germany. Further, the acquisition of Mitotix provided convenient proximity to GPC's long term and continuing collaboration with
ALTANA Pharma AG and the
ALTANA Research Institute, located in
Waltham, Massachusetts.
Products
As of July 2005, the company does not have a marketed product, though it has three therapeutics in its
drug discovery pipeline as shown in the table below.
Notes
# Mission statement obtained from http://www.gpc-biotech.com/en/about_the_company/index.html. Retrieved July 9, 2005.
# A portion of basic corporate information was obtained from
the Hoover's Online Fact Sheet for GPC Biotech AG. Retrieved July 9, 2005.
# reference:
Annual Report for the year 2000. Retrieved July 11, 2005.
# reference:
Annual Report for the year 2004. Retrieved July 11, 2005.